Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: rdcu.be/eLTN1 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.

NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab ipilimumab → • 99% pathologic response • 67% pathologic CR • Zero recurrences to date at 3 years 🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago. The real question now: with Cercek’s rectal data, can we safely omit surgery next? At minimum, this should be the new standard. At maximum, it’s the start of a paradigm shift. @OncoAlert @TheGutOncLab #ESMO25

The mini oral session on #GI cancer continues at #ESMOAsia24 in #Singapore. More abstracts on gastric, gastroesophageal, and GEJ cancer, but also on #BTC and #PDAC @myESMO @DrAngelaLamarca @JenSeligmann

Delighted to have this published. Fantastic effort from all involved! ✅ ICIs transforming Tx of dMMR CRC ✅ Common toxicities now well recognised but... 💥 Is bowel obstruction a rare complication when primary tumour in situ?! International case series in @ESMO_Open ⬇️⬇️⬇️

Abstract titles for #ESMO24 now online! Full NICHE-3 cohort (59 pts with dMMR colon cancer treated with neoadj nivo/rela) will be presented in proferred paper session more neoadj IO from Imhotep, and wonderful @JenSeligmann as discussant. Stay tuned for more exciting💥💥💥news!

Outstanding presentation by ⁦⁦@JenSeligmann⁩ at #ESMOGI24 about neoadj strategies to modify the status quo in localized colon cancer. Academic research will be the key, sure! 💪🏻 ⁦⁦@myESMO⁩ #ESMOAmbassadors